双化蛋白OTUD6B通过稳定RIPK1促进肺腺癌的进展,从而促进肺腺癌的进展
Miaomiao Yang1, Yujie Wei2, Xin He3
1Department of Nephrology, Henan Provincial Key Laboratory of Kidney Disease and Immunology, Henan Provincial Clinical Research Center for Kidney Disease, Henan Provincial People's Hospital and People's Hospital of Zhengzhou University, 7 Weiwu Road, Zhengzhou, 450053, Henan, China. 15736738997@163.com.
在肺腺癌 (LUAD) 中,deubiquitinase OTUD6B 过度表达,促进瘤生长和预后不佳. 针对OTUD6B显示出作为有效的抗LUAD治疗策略的潜力.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 脱化酶与瘤进展有关.
- 这些酶代表了癌症治疗中的潜在治疗点.
研究的目的:
- 研究OTUD6B在肺腺癌 (LUAD) 中的作用.
- 评估OTUD6B作为LUAD的潜在治疗点.
主要方法:
- 免疫组织化学和TCGA/GO数据库对LUAD组织中OTUD6B表达的分析.
- 在体外测试 (细胞活力,细胞亡,迁移,入侵) 和体内异种移植模型.
- 同免疫沉和质谱测量用于识别OTUD6B基质.
主要成果:
- OTUD6B在LUAD中表达很高,与患者预后不佳相关.
- OTUD6B 敲除抑制了 LUAD 细胞的增殖,增强了细胞灭绝,并减少了转移.
- OTUD6B 与 RIPK1 相互作用,减少其无处不在和增加蛋白质稳定性,从而促进瘤生长.
结论:
- OTUD6B是LUAD进展的重要贡献者.
- 向OTUD6B为肺腺癌治疗提供了一个有前途的治疗策略.
更多相关视频
10:21Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
Published on: September 20, 2024
09:40Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
相关概念视频
PI3K/mTOR/AKT Signaling Pathway
Export of Misfolded Proteins out of the ER
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
Regulation of the Unfolded Protein Response
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
The Unfolded Protein Response
